Patentes

ICREA selecciona a los investigadores únicamente en base a sus logros científicos. No obstante, la excelencia científica desemboca a menudo en la invención de nuevas tecnologías y soluciones increíbles. Cuando eso sucede, ICREA apoya plenamente el aprovechamiento de estas oportunidades.

Los catedráticos de investigación de ICREA trabajan en varias universidades y centros de investigación. De ahí que la titularidad de cualquier propiedad industrial se comparta siempre entre ICREA y la institución de acogida. Para que las negociaciones sean lo más ágiles y concluyentes posible, si surge la oportunidad, las instituciones de acogida pueden estudiar y emprender actividades de transferencia de tecnología en nombre de ICREA. ICREA apoya las acciones encaminadas a tal aprovechamiento y presta su asesoramiento durante todo el proceso.

Consulte nuestras tecnologías actuales y contacte con ICREA para saber más.

Busca

  • Life & Medical Sciences
    CAR T-cells for CD1-positive cancer

    Diego Sanchéz, Heleia Roca, Francisco Gutiérrez, Clara Bueno, Pablo Menéndez
    Josep Carreras Leukemi Research Institution

    CLOSE
    CAR T-cells for CD1-positive cancer

    Diego Sanchéz, Heleia Roca, Francisco Gutiérrez, Clara Bueno, Pablo Menéndez
    Josep Carreras Leukemi Research Institution

    The choice of the antigen against which we wish to re-direct T-cells represents a major advance to solve the problems associated with the shared expression of T-cell markers between normal and malignant T-cells. We identified that CD1a, a lipid-presenting molecule, is a suitable target for 5 treating a large subset of T-ALL, i.e. cortical T-ALL. We developed and functionally characterized CD1a-specific CARTs, which displayed robust cytotoxicity against T-ALL cell lines and primary cortical CD1a+ T-ALL cells both in vitro and in vivo in xenograft models. The CD1a CARTs continuously expanded 200-fold, similar to MOCK T-10 cells, demonstrating that redirecting CARTs against CD1a antigen does not induce T-cell fratricide. Also, the use of CD1a CARTs for cortical T-ALL bypasses the need for sophisticatedgenome editingbased disruption of target antigens in T-cells prior to CAR transduction as a strategy to avoid selfantigen-driven fratricide 15-17,19. We further demonstrated that in steady-state hematopoiesis, CD1a is exclusively expressed in a subset of cortical CD34+CD7+ thymic T progenitors, whereas earlier 15 CD34highCD7high T-progenitors lack CD1a. In addition, neither normal CD34+ HSPCs nor mature Tcells from multiple tissues express CD1a during ontogeny, thereby minimizing the risk of ontarget/off-tumor toxicity. Indeed, when human fetal thymus-derived CD7+ thymocytes were exposed to CD1a CARTs, only the CD1a+ cortical thymocytes were eliminated by the CD1a CARTs, while developmentally earlier and later thymic T-lineagepopulations (CD34+ and CD34-) were not targeted, 20 limiting the on-target/off-tumor effects to a developmentally transient thymic population of cortical thymocytes and further confirming thefratricide resistant nature of CD1a CARTs. The exclusive thymic localization of cortical thymocytes, and the fact that thymic subpopulations of CD34+CD7+CD1a- T-cell progenitors physiologically/constantly maturing into functional T cells25 reside upstream of CD1a+ cortical thymocytes, provides an additional level of safety for the use of CD1a CARTs in patients with R/R T-ALL. We do not expect irreversible toxicities or severe T-cell aplasia attributed to CD1a CARTs for the following reasons: i) the CD1a+ thymocyte population is a transient thymic T-cell fraction, eventually regenerated by upstream CD1a- T-cell progenitors; ii) CD1a CARTs themselves respond normally to viral antigens and therefore are likely to be protective 30 against pathogens; iii) the clinical use of specific antibodies against CD5 or CD7 42 did not reveal severe or irreversible toxicities; iv) there are multiple studies that demonstrate extrathymic maturation of T-cells and a balance between the innate and adaptive immune system that may, at least in part, guarantee immunological protection in patients who haveundergone partial or total thymectomy 45-47. 35 Thus, in one aspect, the present invention provides a chimeric antigen receptor (CAR) comprising an extracellular domain comprising a CD1a targeting-moiety, a transmembrane domain, and an intracellular signaling domain. The present invention also provides a nucleic acid encoding the CAR of the present invention. Further, 5 the present invention provides a cell comprising the nucleic acid and/or CAR of the present invention. And, the present invention provides a pharmaceutical composition comprising a plurality of cells in accordance with the present invention and a pharmaceutically acceptable carrier or diluent. The cell of the present invention or pharmaceutical composition of the present invention is provided 10 for use as a medicament. In particular, the present invention provides a method of treating a CD1apositive cancer comprising administering the cell of the present invention or the pharmaceutical composition of the present invention to a patient in need thereof.

    Filing date: 14 Feb, 2019

    EP19382104.8

  • Life & Medical Sciences
    NG2 antigen is a therapeutic target in human acute leukemia

    Pablo Menendez, Clara Bueno, Belen Lopez-Millan, HeleiabRoca-Ho
    Institute Josep Carreras

    CLOSE
    NG2 antigen is a therapeutic target in human acute leukemia

    Pablo Menendez, Clara Bueno, Belen Lopez-Millan, HeleiabRoca-Ho
    Institute Josep Carreras

    Filing date: 4 Aug, 2018

    P14748PCT00

  • Life & Medical Sciences
    METHODS OF QUANTIFYING LIF AND USES THEREOF




    CLOSE
    METHODS OF QUANTIFYING LIF AND USES THEREOF



    Filing date: 18 Jun, 2018

  • Life & Medical Sciences
    COMBINATION OF LIF INHIBITORS AND PLATINUM-BASED ANTINEOPLASTIC AGENTS FOR USE IN TREATING CANCER




    CLOSE
    COMBINATION OF LIF INHIBITORS AND PLATINUM-BASED ANTINEOPLASTIC AGENTS FOR USE IN TREATING CANCER



    Filing date: 18 Jun, 2018

  • Life & Medical Sciences
    METHODS FOR IMPROVING RESPONSE TO ANTI-LIF ANTIBODY TREATMENT IN INDIVIDUALS WITH CANCER




    CLOSE
    METHODS FOR IMPROVING RESPONSE TO ANTI-LIF ANTIBODY TREATMENT IN INDIVIDUALS WITH CANCER



    Filing date: 18 Jun, 2018

  • Life & Medical Sciences
    LIF DOSAGES




    CLOSE
    LIF DOSAGES



    Filing date: 14 May, 2018

  • Life & Medical Sciences
    COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN TREATING CANCER

    Joan Seoane Suárez Judit Anido Folgueira Johan Fransson Robin Matthew Hallett
    Mosaic Biomedicals, S.L.U., et al

    CLOSE
    COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN TREATING CANCER

    Joan Seoane Suárez Judit Anido Folgueira Johan Fransson Robin Matthew Hallett
    Mosaic Biomedicals, S.L.U., et al

    Filing date: 12 Apr, 2018

    18382248.5-1111

  • Engineering Sciences
    Confidential

    V. Pruneri, R. Camphausen
    ICFO and ICREA

    CLOSE
    Confidential

    V. Pruneri, R. Camphausen
    ICFO and ICREA

    Filing date: 30 Nov, 2017

    Licenced date: 21 Sep, 2018

    PCT114973

  • Experimental Sciences & Mathematics
    Photocatalyst system and use thereof in a photocatalytic process

    Shen,Yangyang;Yiting,Gu;Martin,Ruben


    CLOSE
    Photocatalyst system and use thereof in a photocatalytic process

    Shen,Yangyang;Yiting,Gu;Martin,Ruben

    Filing date: 15 Nov, 2017

    EP17382772

  • Engineering Sciences
    ID0097-00 / Confidential

    V. Pruneri, C. Abellán, W. Amaya, M.W. Mitchell
    ICFO and ICREA

    CLOSE
    ID0097-00 / Confidential

    V. Pruneri, C. Abellán, W. Amaya, M.W. Mitchell
    ICFO and ICREA

    Filing date: 6 Nov, 2017

    Licenced date: 24 Nov, 2017

    PCT/ES2017/070734

Pages